Profile data is unavailable for this security.
About the company
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).
- Revenue in USD (TTM)0.00
- Net income in USD-12.59m
- Incorporated2015
- Employees14.00
- LocationCalciMedica Inc505 Coast Boulevard South, Suite 307LA JOLLA 92037United StatesUSA
- Phone+1 (858) 952-5500
- Fax+1 (302) 655-5049
- Websitehttps://calcimedica.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reneo Pharmaceuticals Inc | 0.00 | -56.54m | 50.14m | 8.00 | -- | 0.6522 | -- | -- | -1.68 | -1.68 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
Syros Pharmaceuticals Inc | 4.15m | -131.56m | 52.28m | 68.00 | -- | -- | -- | 12.60 | -4.30 | -4.30 | 0.1222 | -0.2369 | 0.0288 | -- | -- | 61,000.00 | -91.46 | -54.44 | -112.06 | -64.32 | -- | -- | -3,171.70 | -772.82 | -- | -- | 1.18 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Prenetics Global Ltd | 22.25m | -49.97m | 53.27m | 320.00 | -- | 0.2325 | -- | 2.39 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
Intensity Therapeutics Inc | 0.00 | -15.08m | 53.43m | 5.00 | -- | 9.95 | -- | -- | -1.10 | -1.10 | 0.00 | 0.3898 | 0.00 | -- | -- | 0.00 | -112.08 | -- | -146.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
Calcimedica Inc | 0.00 | -12.59m | 53.64m | 14.00 | -- | 3.88 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
Angion Biomedica Corp | 0.00 | -38.66m | 54.63m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
Aerovate Therapeutics Inc | 0.00 | -87.94m | 54.85m | 51.00 | -- | 0.5808 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 56.08m | 49.00 | -- | 1.25 | -- | 692.32 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Hookipa Pharma Inc | 52.16m | -48.60m | 57.14m | 151.00 | -- | 0.6639 | -- | 1.10 | -5.28 | -5.28 | 4.85 | 7.14 | 0.33 | -- | 309.57 | 345,450.30 | -30.74 | -41.63 | -40.15 | -50.26 | -- | -- | -93.16 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
Mural Oncology PLC | 0.00 | -173.30m | 57.59m | 117.00 | -- | 0.2797 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Serina Therapeutics Inc | 179.00k | -18.67m | 58.80m | 4.00 | -- | -- | -- | 328.46 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 783.90k | 7.29% |
Stonepine Capital Management LLCas of 31 Mar 2024 | 522.60k | 4.86% |
Aisling Capital Management LPas of 30 Jun 2024 | 521.11k | 4.85% |
BML Capital Management LLCas of 30 Jun 2024 | 160.42k | 1.49% |
Alyeska Investment Group LPas of 31 Mar 2024 | 75.08k | 0.70% |
Millennium Management LLCas of 31 Mar 2024 | 66.13k | 0.62% |
Meritage Portfolio Management, Inc.as of 30 Jun 2024 | 46.00k | 0.43% |
Geode Capital Management LLCas of 30 Jun 2024 | 44.03k | 0.41% |
Envestnet Asset Management, Inc.as of 30 Jun 2024 | 22.26k | 0.21% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 13.36k | 0.12% |